Womens Health Diagnostics Market Report 2026

The womens health diagnostics market size has grown strongly in recent years. It will grow from $36.88 billion in 2025 to $40.38 billion in 2026 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to increasing prevalence of women-specific diseases, expansion of diagnostic infrastructure, rising awareness of early screening benefits, growth in laboratory testing services, adoption of imaging-based diagnostics.

The womens health diagnostics market size is expected to see strong growth in the next few years. It will grow to $59.02 billion in 2030 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to increasing demand for personalized diagnostics, rising investments in precision testing technologies, expansion of home-based diagnostics, growing integration of ai analytics, increasing focus on preventive screening programs. Major trends in the forecast period include increasing adoption of advanced imaging and testing technologies, rising use of at-home diagnostic kits, growing integration of ai in diagnostic interpretation, expansion of genetic and hormonal testing, enhanced focus on early disease detection.

The increasing demand for personalized medicine is expected to drive the growth of the women’s health diagnostics market in the coming years. Personalized medicine refers to medical approaches that prevent, identify, or treat diseases by leveraging information about an individual’s genes or proteins. This approach enables healthcare providers to develop treatment strategies that are customized to a woman’s specific genetic, molecular, and clinical characteristics. It may include targeted therapies based on genetic indicators or distinct biomarkers. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit research organization, reported that the US Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, an increase from six approvals in 2022. The 2023 approvals also included seven oncology therapies and three treatments addressing other medical conditions. Therefore, the growing demand for personalized medicine is fueling the growth of the women’s health diagnostics market.

Major companies operating in the women’s health diagnostics market are emphasizing product innovation, such as premium ultrasound systems, to maintain their market position. A premium ultrasound system is an advanced medical imaging device designed to produce detailed, high-quality images of internal bodily structures. The premium ultrasound system is part of Samsung’s HERA platform and is specifically developed for obstetrics and gynecology applications. For instance, in February 2023, Samsung’s digital radiography and ultrasound business, a US-based company, introduced the HERA W10 Elite, an advanced women’s health ultrasound system. The system features a range of artificial intelligence (AI)-powered tools and clinical applications, representing a major improvement in diagnostic capabilities for women’s health. The HERA W10 Elite includes advanced functionalities such as MV-Flow for visualizing blood flow intensity, BiometryAssist for efficient fetal growth measurements, and enhanced analytical tools to support clinical diagnosis.

In October 2024, Hologic, a US-based medical technology company, acquired Gynesonics, Inc. for an undisclosed amount. Through this acquisition, Hologic aims to broaden its minimally invasive solutions for women’s health, particularly for the treatment of symptomatic uterine fibroids and heavy menstrual bleeding. By incorporating the Sonata system, Hologic intends to enhance patient outcomes and provide gynecological surgeons with a wider range of treatment options. This strategic acquisition underscores Hologic’s commitment to innovation and expansion in women’s healthcare. Gynesonics is a US-based company specializing in innovative women’s health medical technologies, with a focus on non-invasive treatments for uterine fibroids and women’s health diagnostics.

Major companies operating in the womens health diagnostics market are Becton Dickinson And Company, F. Hoffmann-La Roche AG, General Electric Company, Koninklijke Philips N.V., Quest Diagnostics Incorporated, Siemens Healthineers, Abbott Laboratories, BioMérieux SA, Hologic Inc., PerkinElmer Inc., Alere Inc., Carestream Health Inc., Procter & Gamble Co., Trinity Biotech plc, Medgyn Products Inc., URIT Medical Electronic Co. Ltd, Sonic Healthcare Limited, Fujifilm Holdings Corporation, Thermo Fisher Scientific Inc., Illumina Inc., Myriad Genetics Inc., Agilent Technologies Inc., Bio-Rad Laboratories Inc., Danaher Corporation, Genomic Health Inc., Invitae Corporation, Natera Inc., QIAGEN N.V., Opko Health Inc., Sysmex Corporation, Exact Sciences Corporation, Foundation Medicine Inc., Laboratory Corporation of America Holdings, NeoGenomics Laboratories Inc.

North America was the largest region in the women's health diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global women's health diagnostics market report during the forecast period. The regions covered in the womens health diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the womens health diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the women’s health diagnostics market by increasing costs of imported reagents, imaging equipment, sensors, and diagnostic devices used in laboratories and clinical settings. Diagnostic centers and hospitals in North America and Europe are most affected due to reliance on imported testing equipment, while Asia-Pacific faces cost pressure on manufacturing and exports. These tariffs are increasing test prices and capital investment requirements. However, they are also driving domestic production of diagnostic kits, localized manufacturing of devices, and innovation in cost-efficient diagnostic solutions.

The womens health diagnostics market research report is one of a series of new reports that provides womens health diagnostics market statistics, including womens health diagnostics industry global market size, regional shares, competitors with a womens health diagnostics market share, detailed womens health diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the womens health diagnostics industry. This womens health diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Women’s health diagnostics refers to medical tests and procedures used to assess and diagnose a range of health conditions and diseases that specifically affect women. These diagnostics play a crucial role in early detection, enabling timely treatment and management to improve health outcomes and quality of life.

The primary types of women’s health diagnostics are accessories and consumables, diagnostic tests, and diagnostic devices. Accessories and consumables include various supplementary items and materials used in women’s health-related diagnostic procedures to enhance the accuracy, convenience, and effectiveness of tests and examinations. These are applied across areas such as osteoporosis testing, ovarian cancer testing (OVC), cervical cancer testing, breast cancer testing, pregnancy and fertility testing, prenatal genetic screening and carrier testing, infectious disease testing, sexually transmitted disease (STD) testing, and ultrasound testing. They are utilized by end users including hospitals and clinics, diagnostic and imaging centers, homecare settings, and other healthcare providers.

The women's health diagnostics market includes revenues earned by entities by providing women's health diagnostics, including pregnancy tests, breast imaging equipment, and hormone level tests. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.